Business Wire

Enviva and J-Power Join Efforts to Decarbonize Power Generation in Japan

17.11.2021 05:00:00 EET | Business Wire | Press release

Share

Enviva Partners, LP (NYSE:EVA) (“Enviva”), a global renewable energy company specializing in sustainable wood bioenergy, and Tokyo-based utility Electric Power Development Co., Ltd. (TYO:9513) (“J-Power”), have signed a memorandum of understanding (MOU) for the long-term, large-scale supply of sustainable wood biomass from Enviva's manufacturing facilities in the U.S. Southeast to J-Power’s coal-fired power plants in Japan. The agreement is designed to develop an executable and investable plan under which Enviva will build new infrastructure to produce and deliver up to 5 million metric tons of sustainable wood pellets to permanently replace coal in J-Power’s existing coal-fired power plants, significantly curbing the utility’s greenhouse-gas emissions. The MOU provides a framework to advance the role of biomass as a renewable and sustainable energy source and help J-Power meet its “Blue Mission” goal to be carbon-neutral by 2050.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116006425/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Enviva’s wood pellet storage dome at the Port of Chesapeake in Virginia, U.S. (Photo: Business Wire)

“Climate change is a global challenge requiring a global solution. Enviva has an established track record of delivering a dependable, scalable, and sustainable product, which today delivers substantial and deep decarbonization of energy to generators and industrials around the world,” said Thomas Meth, co-founder and executive vice president of sales and marketing at Enviva. “We are delighted that our partnership with J-Power can help this leading utility in Japan reach its climate goals with reliable, baseload energy that complements the intermittency of wind and solar.”

In April, Japan, the world’s third-largest economy, nearly doubled its 2030 target to cut carbon emissions by 40%, up from 26% in 2013, joining other countries shifting from coal and other fossil fuels to accelerate the fight against climate change. To further align with the government decarbonization policy, J-Power, which has a total of 8.4 gigawatts of coal-fired power capacity, recently announced various plans, including phase-out of aged thermal power plants and co-firing of biomass or ammonia.

Under the agreement, the parties will jointly evaluate the most sustainable and cost-effective means to deliver on the potential of the coal-to-biomass conversion project, such as security of supply, port reception, delivery and storage logistics, safety measures, and project economics. The investment will leverage J-Power’s existing coal-fired power plants by re-purposing them via conversion, resulting potentially in both dedicated as well as co-fired biomass plants.

Converting existing coal-fired power plants to sustainable biomass usage is one of the quickest, most cost-effective ways to reduce the lifecycle greenhouse gas emissions of a plant by more than 80 percent while retaining jobs throughout the supply chain. Coal-to-biomass conversion projects enable former coal plants to continue operating cost-efficiently with their existing supply, generation, and grid infrastructure. Unlike wind and solar energy, biomass is not dependent on grid expansion.

“We are confident that our partnership with Enviva, which has a track record of supplying biomass sustainably and reliably, will firmly support J-Power’s efforts in realizing carbon-neutrality. By combining J-Power’s highly efficient technology to utilize solid fuel and Enviva’s global supply capability, we are meeting the social expectations of achieving carbon neutrality coupled by stable energy supply,” said Shinsuke Suzuki, Executive Officer, Director of Thermal Energy & Value Creation Department at J-Power.

Biomass ultimately provided by Enviva under the agreement will be certified under the European Union’s (EU) current sustainability criteria, which maintains and improves long-term forest health, growth, and capacity. The EU’s sustainability standard guarantees biomass is only sourced from sustainably managed forests that are regenerated, ensuring that carbon stocks are stable or growing, that forest harvesting is legal, and prevents sourcing from nature protection areas, taking soil quality and biodiversity into account.

Earlier this year, Enviva announced its own Net-Zero Commitment that will reduce, eliminate, or offset all of its direct emissions by 2030. Enviva agreed to adopt innovative and improved lower-emission processes through investments in projects that result in real, additional, and third-party verified net-carbon reductions as part of this ambitious plan to cut carbon emissions from fossil fuels and improve energy efficiency.

To learn more about Enviva’s 2030 net-zero plans and goals, click here. To learn more about J-Power’s Blue Mission 2050 initiative, click here.

About Enviva
Enviva (NYSE:EVA) aggregates a natural resource, wood fiber, and processes it into a transportable form, wood pellets. Enviva sells a significant majority of its wood pellets through long-term, take-or pay off-take contracts with creditworthy customers in the United Kingdom, the European Union, and Japan. Enviva owns and operates 10 plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi. In addition, Enviva exports wood pellets through its marine terminals at the Port of Chesapeake, Virginia, the Port of Wilmington, North Carolina, and the Port of Pascagoula, Mississippi, and from third-party marine terminals in Savannah, Georgia, Mobile, Alabama, and Panama City, Florida.

To learn more about Enviva, please visit our website at envivabiomass.com. Follow Enviva on social media @Enviva.

About Electric Power Development Co., Ltd. (J-Power)
Electric Power Development Co., Ltd. (J-Power) is a Japan-based power generator and whole seller. J-Power has 18,250 megawatts (MW) of power generation capacity at 97 locations in Japan. Its hydropower share represents about 47%, and thermal power about 50%, respectively. J-Power is developing renewable power facilities such as wind or geothermal, with a plan to increase capacity to 1,500 MW by 2025. Internationally, J-Power has 6,544 MW of power generation capacity in 33 locations, such as in Thailand, the United States, and China.

On February 26, 2021, J-Power announced its “Blue Mission 2050,” along with its goals to reduce 40% of carbon emission by 2030 compared to three-year average of actual emissions in 2017-2019, and to reach net-zero (carbon neutrality) by 2050. The roadmap includes transition from coal to carbon-free hydrogen, development of renewable power, development of nuclear power as carbon-free source, and expansion of power grid as Japan’s core infrastructure.

Cautionary Note Concerning Forward-Looking Statements
The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included herein, regarding Enviva’s future financial performance, as well as Enviva’s strategy, future operations, financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. When used herein, including any oral statements made in connection herewith, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Enviva disclaims any duty to revise or update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date hereof. Enviva cautions you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Enviva.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Enviva
Maria Moreno
media@envivabiomass.com
+1-301-657-5560

J-Power
+81-3-3546-2211

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release

Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen

AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release

Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer

Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release

Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent

Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release

CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye